dr. brufsky on cobimetinib plus paclitaxel in tnbc
Published 7 years ago • 104 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
4:15
five-year dosing, efficacy results for nab-paclitaxel in tnbc
-
2:10
testing and targeted therapy in triple negative breast cancer: 2023 west oncology
-
1:01
the role of nab-paclitaxel in treating tnbc
-
3:50
clinical approach to triple-negative breast cancer
-
5:45
case 3: atezolizumab/nab-paclitaxel for triple negative breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
1:10
comparing 3 types of targeted therapies for triple-negative breast cancer
-
5:54
case 3: treatment after progression in triple-negative breast cancer
-
0:54
oncology appointments for metastatic triple negative breast cancer #tnbc #breast cancer #radiation
-
3:23
breast cancer: paclitaxel alone or combined with cobimetinib
-
2:20
systemic therapy for recurrent metastatic tnbc
-
1:58
targeted therapy in tnbc
-
27:03
triple negative breast cancer: predictive and prognostic biomarkers for neo/adjuvant therapy
-
4:27
the impassion130 study in metastatic tnbc
-
9:21
combination therapy for tnbc: checkpoint inhibitor chemotherapy
-
7:08
impassion130: results of atezolizumab plus nab-paclitaxel for frontline tnbc
-
1:29
dr. brufsky on the colet trial for triple-negative breast cancer
-
1:17
neoadjuvant immunotherapy in tnbc and targeted lnd in breast cancer: 2023 best of breast conference
-
8:51
advantages with nab-paclitaxel in tnbc